Wall Street brokerages predict that Inovio Pharmaceuticals Inc (NASDAQ:INO) will announce sales of $2.69 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Inovio Pharmaceuticals’ earnings. The lowest sales estimate is $1.05 million and the highest is $5.15 million. Inovio Pharmaceuticals reported sales of $8.79 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 69.4%. The company is scheduled to announce its next quarterly earnings report on Wednesday, March 13th.
According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year sales of $30.67 million for the current fiscal year, with estimates ranging from $29.03 million to $33.13 million. For the next financial year, analysts expect that the company will post sales of $22.98 million, with estimates ranging from $4.21 million to $34.78 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Inovio Pharmaceuticals.
A number of equities analysts have weighed in on the company. BidaskClub downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research raised Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday, January 25th. Finally, Maxim Group reaffirmed a “buy” rating and set a $8.00 price target on shares of Inovio Pharmaceuticals in a research report on Tuesday, January 15th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $9.65.
Several institutional investors have recently made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Inovio Pharmaceuticals by 8.4% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,837 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 2,233 shares in the last quarter. Paloma Partners Management Co raised its stake in shares of Inovio Pharmaceuticals by 38.7% during the 4th quarter. Paloma Partners Management Co now owns 16,201 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 4,522 shares in the last quarter. Squarepoint Ops LLC raised its stake in shares of Inovio Pharmaceuticals by 61.9% during the 4th quarter. Squarepoint Ops LLC now owns 27,011 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 10,331 shares in the last quarter. Northern Trust Corp raised its stake in Inovio Pharmaceuticals by 1.0% in the 4th quarter. Northern Trust Corp now owns 1,048,508 shares of the biopharmaceutical company’s stock valued at $4,194,000 after acquiring an additional 10,768 shares during the period. Finally, Quantamental Technologies LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at $43,000. Institutional investors own 34.10% of the company’s stock.
NASDAQ:INO traded up $0.01 during trading hours on Friday, reaching $3.70. 3,602,100 shares of the stock were exchanged, compared to its average volume of 1,096,432. Inovio Pharmaceuticals has a twelve month low of $3.64 and a twelve month high of $6.30. The company has a market cap of $446.22 million, a P/E ratio of -3.39 and a beta of 1.96.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Recommended Story: LIBOR
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.